SEC Form 4 · accession 0001213900-26-071231
KAZIA THERAPEUTICS LTD · KZIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E. Levine
Officer — Chief Financial Officer
Period of report
Jun 19, 2026
Accepted (ET)
Jun 23, 2026 · 6:47 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001075880
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $13.86 | Jun 19, 2026 | A | 200,000 | A | — | — | ADSs | 200,000 | 200,000 | D |
Explanation of responses
- F1Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.